Peer Review History
| Original SubmissionMarch 3, 2022 |
|---|
|
PONE-D-22-06180Association Between Smoking Behaviors and Dyslipidemia in South Korean AdultsPLOS ONE Dear Dr. jeong, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jun 02 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Negar Rezaei, M.D., Ph.D., Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Please amend your current ethics statement to address the following concerns: a) Did participants provide their written or verbal informed consent to participate in this study? b) If consent was verbal, please explain i) why written consent was not obtained, ii) how you documented participant consent, and iii) whether the ethics committees/IRB approved this consent procedure. 3. Thank you for stating the following financial disclosure: "No" At this time, please address the following queries: a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.” c) If any authors received a salary from any of your funders, please state which authors and which funders. d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.” Please include your amended statements within your cover letter; we will change the online submission form on your behalf. 4. Thank you for stating the following in your Competing Interests section: "No" Please complete your Competing Interests on the online submission form to state any Competing Interests. If you have no competing interests, please state "The authors have declared that no competing interests exist.", as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now This information should be included in your cover letter; we will change the online submission form on your behalf. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #2: Partly Reviewer #3: Partly ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No Reviewer #3: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Dear Editor, This article aims to investigate the association between smoking behaviors including dual smoking (cigarette smoking + e-cigarette), single smoking, and ex-smoking with dyslipidemia using multiple logistic regression. The paper is well-written and well-crafted and the findings are of interest; however, there are some major concerns raised: 1. It would be suggestive to be more attentive about the interpretation of the study findings: a) The authors designed a cross-sectional study to investigate the association between e-cigarettes and dyslipidemia but they modeled dual smoking, which does not correctly reflect the main effect of the e-cigarettes, alone. Therefore, it could be suggested that to discuss and interpret the findings with caution. I highly recommend that the authors go through the manuscript and revise the sections. b) The ORs for dual smoking and single smoking were 1.66 (95% CI = 1.26–2.20) and 1.60 (95% CI =1.41–1.83), respectively. Kindly note that the confidence intervals are crossing and thus there is no statistically significant difference between the ORs of dual and single smoking. Again, I would recommend to be prudent regarding the effect of e-cigarettes on dyslipidemia. Minor comments: m1) Abstract: The conclusions section of the abstract does not inevitably follow the ideas presented in the previous sections of the abstract. Please make sure that all parts of the abstract follow one storyline and are consistent with each other. m2) The introduction is too lengthy and hard-to-follow. Please make it to-the-point. m3) Results: In some parts, the author explained ORs with with words such as "prevalence" as in "Current and former smokers of either electronic or conventional cigarettes presented with a higher prevalence of dyslipidemia compared to non-smokers. These results were statistically significant (ex-smoker: OR = 1.60, 95% CI =1.41–1.83; single smoker: OR = 1.21, 95% CI = 1.06–1.38)." Please go through the manuscript and revise such sentences. Reviewer #2: This study investigates the association between smoking behavior and dyslipidemia using a database in South Korea. The author states that compared to non-smokers and ex-smokers, both single smokers and dual smokers had higher risk of being diagnosed with dyslipidemia, while dual smokers having the highest risk. This is a well-written study. I think this study fits within the scope of PLOS ONE, and it seems to be an interesting paper for the research community in general. Clearly, the large sample size and national institution based random cluster sampling represent strengths of this investigation. Yet, I have some concerns that I would like to address. Major: 1. [Tables] It would be a good idea to mark the data that are statistically significant in Table 2. Also, it would be better to add p-values in the table. 2. Conventional cigarettes are smoked while electronic cigarettes are vaped. I disagree with the phrase "dual smokers," "single smokers," and "electronic cigarettes smokers. "I advise the author to revise the phrase. 3. The introduction addresses the conventional smoking rate of Korean men, but that of electronic cigarettes is not mentioned. Adding the current smoking rate of electronic cigarettes among Koreans would strengthens the point that a lot of smokers are utilizing electronic cigarettes for smoking cessation method. 4. In US, each state has different policies. Regarding cigarettes, for example, San Franciso's Board of Supervisors voted unanimously to ban the sale and distribution of e-cigarettes in the city. I advise the author to add a current policy of Korean government regarding electronic cigarettes in there is any. 5. It would be better if subgroup analysis of few main variables are added. Adding the subgroup analysis of few key variables may help further assessing the relationship between smoking behaviors and dyslipidemia. Reviewer #3: This article aims to investigate the effect of cigarette smoking on dyslipidemia in South Korean adults while including dual smoking as a critical indicator. The subject is novel and interesting, but the study design is unsuitable for the raised question. The authors must correct and explain these points: Title 1. Please consider revising the manuscript title. The title needs to make the main question of the study crystal clear. Abstract 1. Objective: "However, due to the high addictiveness of cigarettes, most individuals end up utilizing both types of cigarettes." The objective of the manuscript, as presented, does not inevitably follow this sentence. I think the rationale of the study objective is missing here. 2. Methods: Please clarify whether the Korean National Health and Nutrition Examination Survey is representative of the Korean population. 3. Methods: Like dyslipidemia, the authors need to present their definition of "smoking status". 4. The results section of the abstract does not correctly reflect the main manuscript's results section. The abstract must be self-explanatory and reflect the most eye-catching researchers' findings. Please revise the abstract and check the representativeness of the core ideas presented in the manuscript. 5. Conclusion: The conclusions section of the abstract does not inevitably follow the ideas presented in the previous sections of the abstract. Please make sure that all parts of the abstract follow one storyline and are consistent with each other. Introduction 1. Consistent with the manuscript objective, the main focus of the study is on the shifting trends in smoking behaviors. Instead, a significant focus of the introduction has been on dyslipidemia. Please revise the introduction's storyline. 2. The current prevalence of all types of smoking is missing in the introduction. The authors need first to present the current situation of tobacco smoking in South Korea. 3. The magnitude of the problem investigated needs to be clarified in the introduction. Instead of subjective quantifiers such as "many", please consider presenting more the absolute values of the epidemiologic measures. For example What proportion of ever/ex/current cigarette smokers switch to e-cigarettes? What proportion quit cigarette smoking successfully after switching to e-cigarettes? 4. Is there any evidence of the deleterious effects of e-cigarettes in any combinations with other tobacco products? This needs to be addressed in the introduction. Methods 1. The methods section lacks cohesion and storyline. Please revise. 2. The inclusion criteria are somewhat unclear. Were men currently smoking at each sprint of the survey included in the study? 3. The merger processes of 2013, 2014, 2015, 2016, and 2019 Korean National Health and Nutrition Examination Survey (KNHANES) data is unclear. Was this a pooled analysis? How did the authors handle duplicates? Were the sampling methods of each survey consistent with others? 4. As the study uses secondary data from KNHANES, more details on KNHANES study protocol need to be provided. Is KNHANES similar to the STEPwise approach to non-communicable disease risk factor surveillance (STEPS) proposed by World Health Organization? The methods section needs to be drafted to empower potential study duplication in the future. 5. The authors need to provide sufficient citations for all the data sources, definitions, etc., presented in the methods. 6. The basis for the occupations classifications needs to be cited and presented in methods. 7. The statistical analysis is insufficiently described. Ensure that all the results presented in the manuscript are derived from the methods presented in this section. Results and Tables 1. Tables 1: Single smokers need to be defined. How many just smoked e-cigarettes/conventional cigarettes? 2. Table 2: The roles of e-cigarettes and conventional cigarettes need to be analyzed separately. Discussion 1. Please initiate the discussion section with the most eye-catching findings of your study. 2. It is necessary to mention the authors' understanding of the article findings well. 3. Please review the discussion, check its storyline, and improve its coherency. It is not easy to follow in its current form. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Seyyed-Hadi Ghamari Reviewer #2: No Reviewer #3: Yes: Mohsen Abbasi-Kangevari [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
Association Between Dual Smoking and Dyslipidemia in South Korean Adults PONE-D-22-06180R1 Dear Dr. jeong, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Negar Rezaei, M.D., Ph.D., Academic Editor PLOS ONE Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Partly Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #3: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #3: No ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) Reviewer #3: Association Between Dual Smoking and Dyslipidemia in South Korean Adults I would like to thank the author for the extensive revision of the manuscript. I think the quality of the manuscript has dramatically improved. A few minor comments: 1. Please consider defining “dual smoking” upon the first appearance in both abstract and the manuscript. 2. Please avoide using personal pronoun i.e. “I, my” in scientific writing. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: Yes: Seyyed-Hadi Ghamari Reviewer #3: Yes: Mohsen Abbasi-Kangevari ********** |
| Formally Accepted |
|
PONE-D-22-06180R1 Association Between Dual Smoking and Dyslipidemia in South Korean Adults Dear Dr. Jeong: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Negar Rezaei Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .